Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Land & Improvements (2016 - 2023)

China Pharma Holdings (CPHI) has disclosed Land & Improvements for 13 consecutive years, with $389808.0 as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Land & Improvements fell 7.12% year-over-year to $389808.0, compared with a TTM value of $389808.0 through Jun 2023, down 7.12%, and an annual FY2022 reading of $404427.0, down 8.46% over the prior year.
  • Land & Improvements was $389808.0 for Q2 2023 at China Pharma Holdings, down from $409895.0 in the prior quarter.
  • Across five years, Land & Improvements topped out at $443697.0 in Q1 2022 and bottomed at $389808.0 in Q2 2023.
  • Average Land & Improvements over 5 years is $416443.1, with a median of $413603.0 recorded in 2020.
  • The sharpest move saw Land & Improvements rose 9.59% in 2021, then fell 8.65% in 2022.
  • Year by year, Land & Improvements stood at $403755.0 in 2019, then increased by 6.92% to $431681.0 in 2020, then rose by 2.34% to $441783.0 in 2021, then dropped by 8.46% to $404427.0 in 2022, then dropped by 3.61% to $389808.0 in 2023.
  • Business Quant data shows Land & Improvements for CPHI at $389808.0 in Q2 2023, $409895.0 in Q1 2023, and $404427.0 in Q4 2022.